Systematic screening for polymorphisms within the UGT1A6 gene in three Chinese populations and function prediction
Pharmacogenomics
|May 20, 2009
Summary
This study characterized UGT1A6 gene polymorphisms in Chinese populations, identifying novel mutations and haplotypes. These findings are crucial for advancing pharmacogenomics and understanding drug metabolism variations in China.
Area of Science:
- Pharmacogenomics
- Human Genetics
- Drug Metabolism
Background:
- Limited research exists on UGT1A6 gene polymorphisms in Chinese populations.
- UGT1A6 plays a role in drug metabolism and detoxification.
- Understanding genetic variations is key to personalized medicine.
Purpose of the Study:
- To determine allele frequencies and haplotypes of the UGT1A6 gene in Chinese ethnic groups.
- To identify and predict the functional significance of UGT1A6 polymorphisms.
- To provide a foundation for pharmacogenomic applications in China.
Main Methods:
- Systematic screening of UGT1A6 polymorphisms using direct sequencing in 1074 subjects from Han, Dong, and She ethnic groups.
- SNP analysis to identify genetic variations.
- Homology modeling to predict the functional impact of mutations on substrate binding.
Main Results:
- Six single nucleotide polymorphisms (SNPs) and 10 mutations were detected, including seven novel ones.
- Identified previously unreported SNPs and mutations in the Chinese population.
- Observed strong linkage disequilibrium and identified seven common haplotypes.
- The P363L mutation may lead to a poor UGT1A6 metabolism genotype.
Conclusions:
- Genetic polymorphisms in UGT1A6 contribute to interindividual and intra-ethnic variability.
- The identified variations and haplotypes are significant for understanding drug response in China.
- These findings support the development of pharmacogenomics in the Chinese population.
Related Concept Videos
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...